What is it about?

Fatty liver disease is increasingly common and is closely linked to obesity, diabetes, and other metabolic problems. Beyond damaging the liver, it may also be associated with an increased risk of cancers, including liver, colorectal, breast, and pancreatic cancer. This review explores how excess fat in the liver, insulin resistance, persistent inflammation, oxidative stress, and changes in cellular energy production may contribute to cancer development. It also examines how genetic differences can influence disease progression and discusses potential treatment targets that researchers are investigating. Understanding these connections may help guide future research into cancer risk assessment, prevention, and treatment for people living with metabolic dysfunction-associated steatotic liver disease (MASLD).

Featured Image

Why is it important?

This review is timely because MASLD affects a large proportion of the global population, yet its potential links with cancers beyond the liver are not widely recognized. A key feature of our work is that it brings together evidence on metabolic disturbances, inflammation, oxidative stress, genetic factors, and cancer-related signaling pathways to explain how these processes may connect fatty liver disease with malignancy. We also discuss emerging therapeutic targets that warrant further investigation. By bringing these findings together, the review highlights important gaps in current knowledge and may help researchers identify new directions for cancer prevention and treatment. However, further clinical studies are needed before these potential strategies can be translated into routine patient care.

Perspectives

I see this publication as an important opportunity to draw attention to a connection between metabolic health and cancer that deserves greater awareness. As a pharmacology researcher, I am particularly interested in understanding the molecular mechanisms linking chronic metabolic disorders to serious long-term complications and identifying pathways that may offer opportunities for therapeutic intervention. Working on this review reinforced my appreciation of the complex interactions between metabolism, inflammation, genetics, and cancer development. I hope this article encourages researchers to explore these connections further and supports future efforts to develop safer, more effective strategies for reducing cancer risk in people with MASLD.

Dr. Shakta Mani Satyam
Ras Al Khaimah Medical and Health Sciences University

Read the Original

This page is a summary of: Nutraceutical Synergy: Unraveling the Protective Effects of Methyl Gallate and Chia Seed Oil in Doxorubicin-induced Hepatic Injury and Bax/Bcl2 Imbalance, Current Pharmaceutical Design, May 2026, Bentham Science Publishers,
DOI: 10.2174/0113816128366802250413160625.
You can read the full text:

Read

Contributors

The following have contributed to this page